Kornimate/medical-research-clean huggingface dataset:
clinical outcomes of cardiovascular disease

Conditions: Cardiovascular Diseases; Heart Failure; Coronary Artery Disease

Summary: this study is a prospective, single center cohort study that primarily registers the clinical characteristics, outcomes, and influencing factors of patients with different types of cardiovascular diseases. evaluate multiple examination indicators of patients at baseline, 1 year and longer, and follow up on the incidence of major cardiovascular and cerebrovascular adverse events, heart failure readmission, death, and other endpoint events.

this study is a prospective, single center cohort study that primarily registers the clinical characteristics, outcomes, and influencing factors of patients with different types of cardiovascular diseases. mainly including coronary heart disease, cardiomyopathy, hypertension, heart failure and other diseases, multiple examination indicators are evaluated for patients at baseline, 1 year and longer periods of time. the primary endpoints for coronary heart disease are all-cause mortality, cardiogenic death, non fatal myocardial infarction, hospitalization for heart failure, and major cardiovascular adverse events. the primary endpoints for cardiomyopathy are all-cause mortality, cardiogenic death, hospitalization for heart failure, and major cardiovascular adverse events. the primary endpoints for hypertension are stroke, all-cause mortality, cardiogenic death, hospitalization for heart failure, and major cardiovascular and cerebrovascular adverse events. the primary endpoints for heart failure are all-cause mortality, cardiogenic death, readmission for heart failure, and major cardiovascular adverse events.

Eligibility criteria:
inclusion criteria: 1. coronary heart disease according to coronary angiography and coronary cta, at least one coronary artery has a degree of stenosis greater than 50%. 2. hypertension hypertension is defined as office systolic blood pressure is ≥ 140mmhg and/or the diastolic blood pressure is ≥ 90mmhg without the use of antihypertensive drugs. 3. heart failure there is a clear history of organic heart disease, clinical symptoms and signs of heart failure, and objective evidence of heart failure. 4. cardiomyopathy including defined dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, etc. 5. able to sign informed consent form. exclusion criteria: 1. age\ 80 years old. 2. patients with various malignant tumors. 3. liver dysfunction (defined as alt or total bilirubin greater than three times the upper normal limit). 4. renal insufficiency (defined as blood creatinine exceeding 1.5 times the upper normal limit). 5. those who have participated in other clinical studies within the past three months. 6. individuals without legal capacity or with limited legal capacity. 7. any situation where the researcher deems it unsuitable to participate in the clinical study.
a study of milvexian in participants after an acute ischemic stroke or high-risk transient ischemic attack- librexia-stroke

Conditions: Ischemic Stroke; Ischemic Attack, Transient

Summary: the purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.


Eligibility criteria:
inclusion criteria: * ischemic stroke: a neurological deficit attributable to an acute brain infarction and national institute of health stroke score scale (nihss) score less than or equal to (\ =) 6 * participants will be randomized as soon as possible after determining eligibility and within 48 hours of onset of event. * current or planned antiplatelet treatment per international and/or local guidelines. if acetyl salicylic acid (asa) is used, it will be limited to low dose (75 to 100 milligrams (mg)/day). loading dose of antiplatelet agents (including asa) are allowed per standard-of-care * a female participant must agree not to be pregnant, breastfeeding, or planning to become pregnant until 4 days (5 half lives) after the last dose of study intervention * willing and able to adhere to the lifestyle restrictions specified in this protocol exclusion criteria: * prior history of intracranial hemorrhage except subarachnoid hemorrhage greater than (\>) 1 year prior with adequate treatment * the index stroke or tia is considered to have a cardio-embolic etiology based on local standard-of-care investigations and for which guidelines recommend anticoagulation * the index stroke or tia considered to have another known cause, not related to athero-thrombotic sources (treatment of acute stroke trial \[toast\] other determined etiology), based on local standard-of-care investigations * increased risk of bleeding, including clinically significant bleeding within the previous 3 months or known bleeding diathesis or known activated partial thromboplastin time (aptt) prolongation or spinal cord hemorrhage or retinal hemorrhage * current active liver disease, eg, acute hepatitis, known cirrhosis, including participants receiving antiviral treatment for hepatitis * known allergies, hypersensitivity, or intolerance to milvexian or its excipients
a phase 1 study of morab-004 in patients with solid tumor (study: morab-004-j081-103)

Conditions: Solid Tumor

Summary: this is a multicenter, multiple doses, open-label phase 1 study of morab-004 in subjects with solid tumors. subjects may have any solid tumor without intracranial involvement or metastases that has failed standard chemotherapy. this study will be conducted in 2 parts: 1) part 1 will be the dose escalation portion of this study to assess the tolerability and the safety profile of morab-004. dose will escalate in different cohorts as follows: 2, 4, 8 and 12 mg/kg weekly dosing each as a 4-week cycle with no intra-subject escalation. individual participants may have additional cycles at the same dose until disease progression unless the participants meet the discontinuation criteria. 2) part 2 will comprise cohort expansions to further characterize the safety and tolerability of morab-004 and to assess preliminary efficacy and the pharmacokinetic/pharmacodynamic relationship of morab-004 in gastric cancer and hepatocellular carcinoma (hcc). three dose levels will be expanded based on the safety profile that was obtained in the dose escalation portion of this study (part 1): 4 mg/kg (administered on a weekly basis), 8 mg/kg (administered on a weekly basis) and 12 mg/kg (administered every other week).


Eligibility criteria:
inclusion criteria: 1. provide written informed consent, 2. japanese male and female subjects aged at 20 or older at informed consent, 3. have malignant solid tumor, without intracranial involvement or metastasis, diagnosed by standard pathology criteria that has failed or are resistant to standard chemotherapy, 4. performance status (ps) is 0 to 1 by eastern cooperative oncology group, 5. with no carry-over effect and no adverse drug reaction of prior treatment which may affect the safety evaluation of morab-004, except for grade 1 or 2 neuropathy and alopecia, 6. survival expectation is 12 weeks or longer after starting morab-004 administration exclusion criteria: 1. have clinically significant cardiovascular disease, 2. scheduled for laparotomic surgery due to trauma or other reasons for during the study, 3. have clinically significant hemorrhagic event or history, or event with high risk of hemorrhage, 4. receiving chronic systemic anticoagulation, 5. have evidence of other active invasive malignancy 6. females who are lactating or pregnant at screening or baseline
ribavirin bioavailability after telaprevir exposure

Conditions: Hepatitis C

Summary: anemia is more frequent in patients receiving telaprevir with pegylated-interferon/ribavirin than in those receiving pegylated-interferon/ribavirin alone. the objective was to measure the impact of telaprevir on ribavirin bioavailability and to assess the concomitant renal function.


Eligibility criteria:
inclusion criteria: * patients with hepatitis c virus infection * previous non-response to pegylated-interferon/ribavirin therapy * re-treatment with pegylated-interferon/ribavirin and telaprevir exclusion criteria: * decompensated liver cirrhosis

Keywords: anemia antiviral agents glomerular filtration rate hepatitis c ribavirin telaprevir
complete digital workflow for construction of full arch implant supported screw retained restoration

Conditions: Accuracy

Summary: aim: to compare the accuracy of the conventional and digital impression when will be performed on implant level or abutment level in complete digital workflow for construction of full arch implant supported screw-retained restoration.

the patient will be selected according to the following criteria: 1. free from any systemic disease that may interfere with proper osseointegration of implants, which will be assessed by thorough medical investigations. 2. patients having completely edentulous maxilla and mandible for at least 6 months after the last extraction. 3. normal maxilla mandibular relationship with adequate inter-arch space, measured by tentative jaw relation. 4. sufficient residual alveolar ridge. exclusion criteria include: 1. local or general contraindications for surgical procedures. 2. patients with tmj disorders or poor neuromuscular coordination or parafunctional habits. 3. severe inter-maxillary skeletal discrepancy or limited inter-arch space. 4. heavy smokers. * for all patients, conventional complete dentures are constructed. * implants installed in the edentulous maxilla and mandible in each target position guided by stereolithographic stent. a delayed loading protocol is followed in this study. * after osseointegration, a conventional open tray splinted impression technique will be made for each patient on the implant/abutment level. * scan bodies' implant level/abutment level will be tightened for each patient, and a digital intraoral scanner will be used to scan the scan bodies for making implant level/abutment level digital impressions. accuracy will be evaluated as follows: * 3d inspection software using the best-fit alignment algorithm will be utilized to calculate the 3d deviation of each impression using the root mean square (rms) error. * passive fit of the framework will be evaluated at the time of insertion.

Eligibility criteria:
inclusion criteria: * free from any systemic disease that may interfere with proper osseointegration of implants, which will be assessed by thorough medical investigations. * patients having completely edentulous maxilla and mandible for at least 6 months after the last extraction. * normal maxilla mandibular relationship with adequate inter-arch space as verified by tentative jaw relation. * sufficient residual alveolar ridge. exclusion criteria: * local or general contraindications for surgical procedures. * patients with tmj disorders or poor neuromuscular coordination or parafunctional habits. * severe inter-maxillary skeletal discrepancy or limited inter-arch space. * heavy smokers.

Keywords: accuracy implant level impression abutment level impression
efficacy of afl-assisted pdt in microinvasive squamous cell carcinoma

Conditions: Microinvasive Squamous Cell Carcinoma

Summary: surgical excision is the standard treatment for cutaneous scc. however, many patients diagnosed with scc are elderly and ineligible for surgery. ablative fractional laser- assisted photodynamic therapy (afl-pdt) offered a higher efficacy than conventional methylaminolevulinate (mal)-pdt.

squamous cell carcinoma (scc) lesions are potentially metastatic and can be life threatening. hence, surgical excision is the standard treatment for cutaneous scc. however, some patients are ineligible for surgery because of their poor general health, concomitant anticoagulant or immunosuppressive therapies, or allergy to local anesthetics. photodynamic therapy (pdt) with methylaminolevulinate (mal) is an innovative treatment modality that has been approved in europe for the treatment of actinic keratosis, basal cell carcinoma, and bowen's disease. however, currently, there is insufficient evidence to support the routine use of topical pdt for scc. ablative fractional laser (afl) ablates the epidermis and dermis without significant thermal injury, creating microscopic ablation zones in the portion of the skin that the laser is applied to. our previous studies showed that afl-primed mal-pdt (afl-pdt) offered a higher efficacy than conventional mal-pdt in the treatment of many other diseases, such as actinic keratosis, actinic cheilitis, and bowen's disease. investigators recruited korean patients with microinvasive scc and compared the efficacy, recurrence rate, and cosmetic outcomes of afl-pdt with those of standard mal-pdt.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or more who had previously untreated microinvasive scc, providing they satisfied both of the following conditions: * tumor invasion into the papillary dermis (clark level ii) according to a biopsy specimen and * difficulty in surgical excision because of health problems (bleeding tendency or cardiac problems) exclusion criteria: * pregnancy or lactation * active systemic infectious disease * other inflammatory, infectious, or neoplastic skin diseases in the treated area * allergy to mal,other topical photosensitizers, or excipients of the cream * history of photosensitivity * use of immunosuppressive or photosensitizing drugs * participation in any other investigational study in the preceding 30 days * history or indicators of poor compliance * histological findings of acantholysis, desmoplasia, perineural or lymphovascular invasion, and echographic features of regional lymph node metastasis were the disease-specific exclusion criteria

Keywords: ablative fractional laser microinvasive squamous cell carcinoma photodynamic therapy
urinary catheter self-discontinuation after urogynecology surgery

Conditions: Urinary Retention; Pelvic Organ Prolapse; Stress Urinary Incontinence; Catheter Related Complication

Summary: the goal of this randomized clinical trial is to determine if removal of transurethral urinary catheters by patients at home is as safe as catheter removal in the office following urogynecologic surgery. participants will be randomized to either standard catheter removal in the office or catheter self-removal at home.

this is a prospective, randomized, two-parallel arm, non-inferiority trial to evaluate two methods of catheter discontinuation in women with post-operative urinary retention (pour) after surgery for pelvic organ prolapse (pop) or stress urinary incontinence (sui). this study will evaluate whether self-discontinuation of transurethral catheter by patients is non-inferior to standard office discontinuation based on rates of persistent pour on post-operative day (pod) 1.

Eligibility criteria:
inclusion criteria: 1. are at least 18 years of age 2. are fluent and able to read in english or spanish 3. undergo pop and/or sui surgery (uterosacral ligament suspension, sacrospinous ligament fixation, sacral colpopexy, anterior colporrhaphy, posterior colporrhaphy, and/or mid-urethral sling) that occurs on monday - thursday 4. have transurethral catheter in place at the conclusion of surgery as part of standard care 5. are diagnosed with pour on pod0 based on ultrasound bladder scan pvr of 100 ml or more 6. are discharged home on the same day of surgery (pod 0) exclusion criteria: 1. have preoperative voiding dysfunction requiring self-catheterization or indwelling transurethral catheter 2. have physical or mental impairment that would impact their ability to remove their catheter themselves. 3. undergo urethral bulking injections as part of surgery 4. have undergone a planned or unplanned urinary tract procedure requiring prolonged catheterization as standard of care (e.g. cystotomy repair, ureteral reimplantation, vesicovaginal fistula repair, urethral diverticulum repair)

Keywords: post-operative urinary retention pelvic organ prolapse stress urinary incontinence cather self-discontinuation
psychological vulnerabilities and transgender adolescents: a descriptive epidemiology study

Conditions: Gender Dysphoria, Adolescent

Summary: the number of adolescents engaging in a transidentity journey has been increasing rapidly over the last decade. however, the knowledge of the medical world concerning the specificities of these adolescents is still too little in france. the objective of this study is to refine the knowledge of the different health care providers who are brought to meet these adolescents. this research proposes to study more specifically the register of psychological vulnerabilities: to cite only a few examplesthese include disorders such as depression, anxiety disorders and eating disorders, all of which cause suffering and difficulties in everyday life. a better understanding of the presence or absence and the distribution of these different types of vulnerabilities among transgender adolescents would allow, among other things, to promote their their screening by health care providers. this better screening would allow doctors to physicians to offer targeted treatment for these disorders in parallel with the transition process. transition process.


Eligibility criteria:
inclusion criteria: * be between 12 and 18 years old * be followed up at the gender consultation of the toulouse university hospital exclusion criteria: * have not yet completed the first consultation on gender issues at the time of selection. * have only one last appointment with the gender consultation at the time of selection

Keywords: mental disorders
iota ultrasound criteria and serum ca 125 for ovarian malignancy detection

Conditions: Ovarian Neoplasms; Ovarian Cancer; Ovarian Carcinoma

Summary: this cross-sectional analytic study assessed the diagnostic accuracy of iota simple rules versus serum ca 125 in women with adnexal masses undergoing surgery. eighty-two percent of tumors were classifiable by iota criteria; ca 125 cut-offs of 35, 70, and 105 u/ml were evaluated against histopathology gold standard.

all women admitted to the department of obstetrics and gynecology and assigned for the surgery of adnexal mass were enrolled in the study. after written informed consent, the clinical proforma was filled up. data collection regarding age, current or previous hormonal contraception, menopausal status and family history of breast or ovarian cancer, clinical presentation. participants were scheduled for ultrasound evaluation done according to iota simple rules (five malignant features and five benign features) and peripheral blood was collected for tumor marker serum ca125 measurement. during ultrasonographic examination, the morphology of the adnexal masses was characterized using 2d real-time and color doppler ultrasound. adnexal masses were described according to origin (ovarian/extra ovarian); position (right/left/bilateral); number of lesions; type of lesions (unilocular/unilocular - solid/multilocular/multilocular - solid); size; volume; intracystic fluid echogenicity; number of locations; presence and size of septations; presence, number, size of solid papillary projections; largest solid component; presence / absent of ascites. these parameters are used as designation according to iota group. for the sample of ca125, approximately 2 ml blood was collected and registered patient's hospital number, then the selected reagent was added to the sample and kept in a fully automated immunoassay system in the hospital laboratory where electrochemiluminescence immunoassay method (eclia) is used for the analysis. surgery was performed in the hospital and a biopsy was sent for the histopathology examination in the same hospital. sensitivity, specificity, positive predictive value, and negative predictive values of ca125 and iota class were calculated. the correlation between ca 125 and iota simple rules was analyzed and compared with histopathological reports using the pearson correlation method. the area under the receiver operating characteristic curve (auc) was used to determine the point at which ca125 had the highest sensitivity and specificity in distinguishing histologically malignant from benign tumors.

Eligibility criteria:
inclusion criteria: * all age groups and parity with ovarian mass admitted for scheduled surgery. exclusion criteria: * proven cases of ovarian malignancy * ovarian mass in pregnancy

Keywords: iota ca 125 ultrasonography ovarian malignancy
biomarkers in friedreich's ataxia

Conditions: Friedreich's Ataxia

Summary: the purpose of this project is to characterize measures of cardiac performance and neuromuscular physiology in fa patients using novel techniques, including echocardiography and magnetic resonance imaging (mri), metabolic exercise testing, and neurophysiological outcomes.

friedreich's ataxia (fa) is an autosomal recessive disease caused by a mutation in the frataxin gene (fxn). although rare, fa is the most common form of hereditary ataxia, affecting 1 in every 50,000 people in the united states. currently, palliative therapies are the only treatment for fa patients. however, current gene therapy efforts in other neuromuscular diseases have positioned the investigator's research program to extend these discoveries and techniques to fa. as new therapies become available for clinical application, it is crucial to identify non-invasive outcomes measures of cardiac and neuromuscular performance with adequate sensitivity to detect the impact of treatments.

Eligibility criteria:
inclusion criteria: * genetic diagnosis of friedreich's ataxia by dna sequencing, mutational analysis or protein assay or be a healthy subject with no evidence of a neuromuscular disorder * between the ages of 8 and 70 (inclusive) * are able to tolerate metabolic exercise testing * are stable on cardiac medication regimen for 3 months prior to screening exclusion criteria: * presence of unstable heart disease * receipt of cardiac transplant * any concurrent medical condition which, in the opinion of the investigators, would make the subject unsuitable for the study

Keywords: ataxia neuromuscular